A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy

Daniel A. Ferraz, Lisa M. Vasquez, Rony C. Preti, Augusto Motta, Raafay Sophie, Millena G. Bittencourt, Yasir J. Sepah, Mário L R Monteiro, Quan Dong Nguyen, Walter Yukihiko Takahashi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

PURPOSE:: To compare the efficacy of panretinal photocoagulation (PRP) and intravitreal ranibizumab injection with PRP alone in patients with treatment-naive bilateral non-high-risk proliferative diabetic retinopathy. METHODS:: Sixty eyes of 30 patients were randomized either to the study group (SG) receiving PRP plus 2 ranibizumab injections or to the control group (CG) receiving PRP alone. Mean change in best-corrected visual acuity and in optical coherence tomography were compared at baseline and 1, 3, and 6 months. RESULTS:: Best-corrected visual acuity was significantly better at 6 months in the SG; however, there was decrease in best-corrected visual acuity in the CG. Central macula thickness decreased significantly at 6 months in SG when compared with baseline (-47.6 μm, P < 0.001) and did not reveal significant difference in the CG. In eyes with diabetic macular edema, best-corrected visual acuity increased by 3.6 letters (P = 0.06) in the SG and decreased by 4.4 letters in the CG (P = 0.003). Central macula thickness decreased by 69.3 μm (P = 0.001) in the SG and decreased by 45.5 μm (P = 0.11) in the CG. CONCLUSION:: Intravitreal ranibizumab in combination with PRP can be an effective treatment in eyes with non-high-risk proliferative diabetic retinopathy and diabetic macular edema.

Original languageEnglish (US)
Pages (from-to)280-287
Number of pages8
JournalRetina
Volume35
Issue number2
DOIs
StatePublished - Feb 6 2015

Fingerprint

Light Coagulation
Diabetic Retinopathy
Randomized Controlled Trials
Visual Acuity
Control Groups
Macular Edema
Therapeutics
Intravitreal Injections
Optical Coherence Tomography
Ranibizumab
Injections

Keywords

  • panretinal photocoagulation
  • proliferative diabetic retinopathy
  • ranibizumab

ASJC Scopus subject areas

  • Ophthalmology

Cite this

A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy. / Ferraz, Daniel A.; Vasquez, Lisa M.; Preti, Rony C.; Motta, Augusto; Sophie, Raafay; Bittencourt, Millena G.; Sepah, Yasir J.; Monteiro, Mário L R; Nguyen, Quan Dong; Takahashi, Walter Yukihiko.

In: Retina, Vol. 35, No. 2, 06.02.2015, p. 280-287.

Research output: Contribution to journalArticle

Ferraz, DA, Vasquez, LM, Preti, RC, Motta, A, Sophie, R, Bittencourt, MG, Sepah, YJ, Monteiro, MLR, Nguyen, QD & Takahashi, WY 2015, 'A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy', Retina, vol. 35, no. 2, pp. 280-287. https://doi.org/10.1097/IAE.0000000000000363
Ferraz, Daniel A. ; Vasquez, Lisa M. ; Preti, Rony C. ; Motta, Augusto ; Sophie, Raafay ; Bittencourt, Millena G. ; Sepah, Yasir J. ; Monteiro, Mário L R ; Nguyen, Quan Dong ; Takahashi, Walter Yukihiko. / A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy. In: Retina. 2015 ; Vol. 35, No. 2. pp. 280-287.
@article{b1f7549e5527493abab71ba9c70a3ecd,
title = "A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy",
abstract = "PURPOSE:: To compare the efficacy of panretinal photocoagulation (PRP) and intravitreal ranibizumab injection with PRP alone in patients with treatment-naive bilateral non-high-risk proliferative diabetic retinopathy. METHODS:: Sixty eyes of 30 patients were randomized either to the study group (SG) receiving PRP plus 2 ranibizumab injections or to the control group (CG) receiving PRP alone. Mean change in best-corrected visual acuity and in optical coherence tomography were compared at baseline and 1, 3, and 6 months. RESULTS:: Best-corrected visual acuity was significantly better at 6 months in the SG; however, there was decrease in best-corrected visual acuity in the CG. Central macula thickness decreased significantly at 6 months in SG when compared with baseline (-47.6 μm, P < 0.001) and did not reveal significant difference in the CG. In eyes with diabetic macular edema, best-corrected visual acuity increased by 3.6 letters (P = 0.06) in the SG and decreased by 4.4 letters in the CG (P = 0.003). Central macula thickness decreased by 69.3 μm (P = 0.001) in the SG and decreased by 45.5 μm (P = 0.11) in the CG. CONCLUSION:: Intravitreal ranibizumab in combination with PRP can be an effective treatment in eyes with non-high-risk proliferative diabetic retinopathy and diabetic macular edema.",
keywords = "panretinal photocoagulation, proliferative diabetic retinopathy, ranibizumab",
author = "Ferraz, {Daniel A.} and Vasquez, {Lisa M.} and Preti, {Rony C.} and Augusto Motta and Raafay Sophie and Bittencourt, {Millena G.} and Sepah, {Yasir J.} and Monteiro, {M{\'a}rio L R} and Nguyen, {Quan Dong} and Takahashi, {Walter Yukihiko}",
year = "2015",
month = "2",
day = "6",
doi = "10.1097/IAE.0000000000000363",
language = "English (US)",
volume = "35",
pages = "280--287",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy

AU - Ferraz, Daniel A.

AU - Vasquez, Lisa M.

AU - Preti, Rony C.

AU - Motta, Augusto

AU - Sophie, Raafay

AU - Bittencourt, Millena G.

AU - Sepah, Yasir J.

AU - Monteiro, Mário L R

AU - Nguyen, Quan Dong

AU - Takahashi, Walter Yukihiko

PY - 2015/2/6

Y1 - 2015/2/6

N2 - PURPOSE:: To compare the efficacy of panretinal photocoagulation (PRP) and intravitreal ranibizumab injection with PRP alone in patients with treatment-naive bilateral non-high-risk proliferative diabetic retinopathy. METHODS:: Sixty eyes of 30 patients were randomized either to the study group (SG) receiving PRP plus 2 ranibizumab injections or to the control group (CG) receiving PRP alone. Mean change in best-corrected visual acuity and in optical coherence tomography were compared at baseline and 1, 3, and 6 months. RESULTS:: Best-corrected visual acuity was significantly better at 6 months in the SG; however, there was decrease in best-corrected visual acuity in the CG. Central macula thickness decreased significantly at 6 months in SG when compared with baseline (-47.6 μm, P < 0.001) and did not reveal significant difference in the CG. In eyes with diabetic macular edema, best-corrected visual acuity increased by 3.6 letters (P = 0.06) in the SG and decreased by 4.4 letters in the CG (P = 0.003). Central macula thickness decreased by 69.3 μm (P = 0.001) in the SG and decreased by 45.5 μm (P = 0.11) in the CG. CONCLUSION:: Intravitreal ranibizumab in combination with PRP can be an effective treatment in eyes with non-high-risk proliferative diabetic retinopathy and diabetic macular edema.

AB - PURPOSE:: To compare the efficacy of panretinal photocoagulation (PRP) and intravitreal ranibizumab injection with PRP alone in patients with treatment-naive bilateral non-high-risk proliferative diabetic retinopathy. METHODS:: Sixty eyes of 30 patients were randomized either to the study group (SG) receiving PRP plus 2 ranibizumab injections or to the control group (CG) receiving PRP alone. Mean change in best-corrected visual acuity and in optical coherence tomography were compared at baseline and 1, 3, and 6 months. RESULTS:: Best-corrected visual acuity was significantly better at 6 months in the SG; however, there was decrease in best-corrected visual acuity in the CG. Central macula thickness decreased significantly at 6 months in SG when compared with baseline (-47.6 μm, P < 0.001) and did not reveal significant difference in the CG. In eyes with diabetic macular edema, best-corrected visual acuity increased by 3.6 letters (P = 0.06) in the SG and decreased by 4.4 letters in the CG (P = 0.003). Central macula thickness decreased by 69.3 μm (P = 0.001) in the SG and decreased by 45.5 μm (P = 0.11) in the CG. CONCLUSION:: Intravitreal ranibizumab in combination with PRP can be an effective treatment in eyes with non-high-risk proliferative diabetic retinopathy and diabetic macular edema.

KW - panretinal photocoagulation

KW - proliferative diabetic retinopathy

KW - ranibizumab

UR - http://www.scopus.com/inward/record.url?scp=84922399622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922399622&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000000363

DO - 10.1097/IAE.0000000000000363

M3 - Article

C2 - 25272318

AN - SCOPUS:84922399622

VL - 35

SP - 280

EP - 287

JO - Retina

JF - Retina

SN - 0275-004X

IS - 2

ER -